Viking Therapeutics' stock surged 15% after its experimental weight loss pill, VK2735, demonstrated significant weight loss in a 28-day phase 1 trial.
Viking Therapeutics' stock jumped over 15% after the company reported promising results from a phase 1 clinical trial of its experimental weight loss pill. The company's VK2735 drug showed significant weight loss in a 28-day study, with patients experiencing up to 3.3% placebo-adjusted mean weight loss. The results have raised expectations for the biotech company's potential in the weight loss market.
March 26, 2024
24 Articles